| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.32 | 3e-09 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 2e-06 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.18 | 8e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.29 | 9e-06 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.26 | 3e-05 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.23 | 0.0003 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0008 |